Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 121-128

  Johansen, Odd Erik ^a   Vanberg, Pål Johan ^a   Kilhovd, Bente Kvarv ^b   Jørgensen, Anders Palmstrøm ^a  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Efficacy; HbA1c; Insulin; Observational study; Type 1 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; ARTHRALGIA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EVENING DOSAGE; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; TREATMENT DURATION; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67449100810     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ogle G, Beran D, Raab R, Deeb L. On behalf of the Task Force on Insulin, Test Strips and Other Diabetes Supplies. Global access to and availability of insulin. Diabetes Voice. 2006;51:22-25.
2. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174-183.
3. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;5:648-659.
4. Jehle PM, Micheler C, Jehle DR, et al. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet. 1999;354:1604-1607.
5. Larger E. Weight gain and insulin treatment. Diabetes Metab. 2005;31:4S51-4S56.
6. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-2679.
7. Barnett AH. Insulin glargine in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag. 2006;2:59-67.
8. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498-1504.
9. Philips JC, Scheen A. Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag. 2006;2:277-283.
10. Heise T, Nosek L, Rønn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
11. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced Hypoglycemia Risk With Insulin Glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-955.
12. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
13. Chatterjee S, Jarvis-Kay J, Rengarajan T et al. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract. 2007;77:215-222.
14. Bartley PC, Bogoev M, Larsen J, et al. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008;25:442-449.
15. Report No. 18 to the Storting (2004-2005). On course towards more correct use of medicine - Medicinal Product Policy. Accessed Nov 13th 2008.URL: http://www.regjeringen.no/Upload/HOD/Dokumenter%20LMS/ Utdrag%20fra%20legemiddelmeldingen%20oversatt%20til%20engelsk.pdf.
16. Levorsen A, Kristiansen IS, Aasland OG. Physicians' experience with increased use of individual reimbursement for pharmaceuticals. Tidsskr Nor Laegeforen. 2008;128:1829-1832.
17. The Norwegian Labour and Welfare Organisation 2008. Accessed Sept 6th 2008. URL: http://rundskriv.nav.no/rtv/lpext.dll?f=templates&fn=main-j. htm&2.0.
18. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245-1249.
19. Kanazawa Y, Igarashi Y, Komiya K, et al. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2). Endocr J. 2007;54:975-983.
20. Päivärinta M, Tapanainen P, Veijola R. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2008;9:83-90.
21. Pieber TR, Treichel H-C, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24:635-642.
22. www.novonordisk-trials.com. 2008. Safety and efficacy of insulin detemir plus insulin aspart against insulin glargine plus insulin aspart as mealtime insulin in type 1 diabetes. Accessed May 8th 2008. URL: http://www.novonordisk- trials.com/website/search/trial-result-details.aspx?id=1057&p=1&search= t ()
23. Currie CJ, Poole CD, Tetlow T, et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin. 2007;23(S1):33-39.
24. Dornhorst A, Lüddeke HJ, Honka M, et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin. 2008;24:369-376.
25. Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2008;16;(3):CD006297.
26. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140-1147.
27. Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004;27:632-633.
28. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23:879-886.
29. Garg S, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diab Res Clin Pract. 2004;66:49-56.
30. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
31. Ashwell SG, Bradley C, Stephens JW, et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with Type 1 diabetes. Diabetes Care. 2008;31:1112-1117.